CaaMTech

Actual: Sep 8, 2021

$22M Series A led by Noetic Psychedelic Fund

Why it matters: Substantial Series A provides multi-year runway for IND-enabling studies and initial clinical development. CaaMTech holds 50+ patents across novel tryptamine chemistry — one of the largest psychedelic IP portfolios in the industry.

Actual: Nov 14, 2024

FDA endorses functional unblinding strategy for CT-4201 in MDD clinical trials

Why it matters: Functional unblinding is a critical trial design challenge for psychedelic drugs — patients can typically tell if they received the active dose. FDA endorsement of CaaMTech's blinding strategy clears a major regulatory hurdle that has troubled other psychedelic sponsors. This positions CT-4201 for a rigorous, double-blind Phase 1/2 design.

Actual: Jan 1, 2025

Research paper published with NIDA, RTI International, UMass Dartmouth, and Medical College of Wisconsin on tryptamine structure-activity relationships

Why it matters: Multi-institutional NIDA collaboration validates CaaMTech's tryptamine chemistry expertise and builds the scientific foundation for CT-4201 and the broader pipeline.

Actual: Apr 22, 2025

Spun out Transneural Therapeutics Inc. to develop non-hallucinogenic neuroplastogens (TN-001: dual 5-HT2A partial agonist / 5-HT2B antagonist for MDD/PTSD)

Why it matters: Transneural spinout separates CaaMTech's non-hallucinogenic pipeline into a dedicated entity, allowing CT-4201 (hallucinogenic psilocin prodrug) and TN-001 (non-hallucinogenic) to pursue independent clinical strategies and fundraising. Led by CEO Charmaine Lykins.

Watch next: CT-4201 IND filing; Phase 1 FIH initiation; Transneural TN-001 preclinical data